Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DHNP-2302
- Development stage
- Preclinical
- Lead developer
- Daehan Nupharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DHNP-2302 is a small molecule drug candidate currently under development by the South Korean pharmaceutical company Daehan Nupharm for the treatment of obesity. As part of Daehan Nupharm's metabolic disease pipeline, it is being investigated for its potential to manage body weight and address metabolic disorders. While specific details regarding its molecular target and pharmacological mechanism of action have not been fully disclosed by the developer, the candidate represents the company's strategic effort to expand its portfolio in the high-growth obesity market. It is currently in the early stages of development, following the company's established interest in weight management solutions.
Beyond the preview
Go deeper on DHNP-2302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DHNP-2302.